Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Trading R&D

Thursday, October 13, 2016 4:38
% of readers think this story is Fact. Add your two cents.

(Before It's News)

I read this post this morning on why this fintech analyst and investor is “short ethereum”.

The pro-bitcoin and anti-ethereum arguments are interesting and worth digesting if you are into the blockchain sector as I am.

But more interesting to me is that we are talking about some fairly cutting edge computer science here. Ethereum is still very much a work in progress. A computer science experiment. And a very ambitious one too.

And yet they are tradeable, like stocks, bonds, currencies, etc. You can short them or put on a hedged trade (long BTC/short ETH).

Biotech has long been like this. There are publicly traded biotech companies that are doing cutting edge science and you can place bets on wether these experimental projects will succeed in developing some new medical miracle, or not.

But “tech” has not really been like that. You had to be an angel or early stage investor to make these sorts of bets in the software sector.

Not any more. You can buy and sell alt-coins, token, ICOs, or whatever else you want to call these digital assets.

It is fascinating to see this happening and think about where it might go.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.